成人罗马IV功能性恶心和呕吐障碍的流行病学、临床特征及相关因素
2015年对3个英语国家5931名成人进行互联网横断面健康调查,2.2%符合罗马IV功能性恶心和呕吐障碍症状诊断标准,美国患病率高于加拿大和英国;患者健康损害和医疗利用显著高于对照,热水沐浴缓解呕吐症状在功能性呕吐障碍中常见且与大麻使用相关。
要点
- 罗马IV功能性恶心和呕吐障碍总体患病率2.2%,美国3%高于加拿大1.9%和英国1.8%(P=0.02)。
- 周期性呕吐综合征患者中44%报告强迫性热水沐浴以缓解呕吐症状,显著高于慢性恶心呕吐综合征的19%(P=0.03)。
- 功能性恶心和呕吐障碍与较年轻年龄、躯体症状严重度增加、生活质量降低、肠易激综合征和功能性消化不良独立相关。
核心结论
- 基于3个英语国家成人横断面健康调查,约2%受试者符合罗马IV功能性恶心和呕吐障碍症状标准,并存在相当的健康损害。
- 热水沐浴缓解呕吐症状在所有功能性恶心和呕吐障碍中均有报告,并因大麻使用而持续。
研究设计与样本
- 2015年互联网横断面健康调查,纳入3个英语国家一般人群5931名成人,其中美国、加拿大或英国2100名参与者,采用配额抽样生成人口学平衡且具人群代表性的样本。
- 调查收集人口学、就医、药物、躯体症状严重度、生活质量及罗马IV功能性恶心和呕吐障碍、肠易激综合征和功能性消化不良的症状诊断标准数据,并将罗马IV功能性恶心和呕吐障碍受试者与无该障碍个体(对照)比较。
主要发现
- 总体2.2%(n=131)符合罗马IV功能性恶心和呕吐障碍症状诊断标准;美国患病率3%高于加拿大1.9%或英国1.8%(P=0.02)。
- 慢性恶心和呕吐综合征患病率各国相似,范围0.8%至1.2%;周期性呕吐综合征患病率美国2%高于加拿大0.7%或英国1%(P=0.03)。
- 周期性呕吐综合征受试者中使用大麻的比例各国间无显著差异(P=0.31),但7例大麻素剧吐综合征病例均在美国。
- 周期性呕吐综合征受试者报告强迫性热水沐浴以缓解呕吐症状的比例显著高于慢性恶心和呕吐综合征受试者(44% vs 19%;P=0.03),该行为独立于大麻但被其使用增强。
- 功能性恶心和呕吐障碍受试者健康损害和医疗利用显著高于对照;多变量分析中独立相关因素为较年轻年龄、躯体症状严重度增加、生活质量降低、肠易激综合征和功能性消化不良。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Functional nausea and vomiting disorders (FNVDs) are classified as chronic nausea and vomiting syndrome (CNVS) or cyclic vomiting syndrome (CVS)-CVS includes cannabinoid hyperemesis syndrome. We investigated the population prevalence of FNVDs, their characteristics, and associated factors. METHODS: In the year 2015, an Internet cross-sectional health survey was completed by 5931 adults in the general populations of 3 English-speaking countries; 2100 participants were in the United States, Canada, or the United Kingdom. Quota-based sampling was used to generate demographically balanced and population-representative samples. The survey collected data on demographics, health care visits, medications, somatic symptom severity, quality of life, and symptom-based diagnostic criteria for Rome IV FNVDs as well as for irritable bowel syndrome and functional dyspepsia. Subsequent comparisons were made between Rome IV FNVD subjects and individuals without FNVDs (controls). RESULTS: Overall, 2.2% of the population (n = 131) fulfilled symptom-based diagnostic criteria for Rome IV FNVDs: the United States (3%) had a greater prevalence than Canada (1.9%) or the United Kingdom (1.8%) (P = .02). The prevalence of CNVS was similar among the countries, ranging from 0.8% to 1.2%. However, the prevalence of CVS was higher in the United States (2%) than in Canada (0.7%) or the United Kingdom (1%) (P = .03). The proportion of subjects with CVS taking cannabis did not differ significantly among countries (P = .31), although the 7 cases of cannabinoid hyperemesis syndrome were in the United States. A significantly higher proportion of subjects with CVS reported a compulsive need for hot water bathing to alleviate emetic symptoms than subjects with CNVS (44% vs 19%; P = .03); this behavior was independent of cannabis but augmented by its use. Subjects with FNVDs had significantly greater health impairment and health care utilization than controls. On multivariate analysis, independent factors associated with FNVDs were younger age, increasing somatic symptom severity, lower quality of life, presence of irritable bowel syndrome, and functional dyspepsia. However, on subgroup analysis, somatic symptom severity was associated with CVS but not CNVS, whereas poor quality of life was associated with CNVS but not CVS. CONCLUSIONS: Based on a cross-sectional health survey of adults in the general populations of 3 English-speaking countries, approximately 2% of subjects meet symptom-based criteria for Rome IV FNVDs and have considerable health impairments. Hot water bathing to alleviate emetic symptoms is reported for all FNVDs, and is perpetuated by cannabis use.
引用
- Aziz I, Palsson OS, Whitehead WE, et al. Epidemiology, Clinical Characteristics, and Associations for Rome IV Functional Nausea and Vomiting Disorders in Adults. Clin Gastroenterol Hepatol. 2018. PMID: 29857155. doi:10.1016/j.cgh.2018.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。